The discovery and development of romidepsin for the treatment of T-cell lymphoma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The discovery and development of romidepsin for the treatment of T-cell lymphoma
Authors
Keywords
-
Journal
Expert Opinion on Drug Discovery
Volume -, Issue -, Pages 1-15
Publisher
Informa UK Limited
Online
2017-06-23
DOI
10.1080/17460441.2017.1341487
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma
- (2017) Beata Holkova et al. LEUKEMIA & LYMPHOMA
- Reactive Oxygen Species–Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid Malignancies
- (2017) Monish R. Makena et al. MOLECULAR CANCER THERAPEUTICS
- Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms
- (2017) Manli Jiang et al. Expert Review of Hematology
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms
- (2016) S. H. Swerdlow et al. BLOOD
- The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma
- (2016) Dai Chihara et al. BRITISH JOURNAL OF HAEMATOLOGY
- HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
- (2016) Hong Zheng et al. CLINICAL CANCER RESEARCH
- Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study
- (2016) Rena Buckstein et al. Clinical Lymphoma Myeloma & Leukemia
- Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides
- (2016) Francine Foss et al. Clinical Lymphoma Myeloma & Leukemia
- Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas
- (2016) Pier Luigi Zinzani et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Romidepsin for the treatment of relapsed/refractory cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome): Use in a community setting
- (2016) Sunil A. Reddy CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
- (2016) Cinzia Pellegrini et al. Journal of Hematology & Oncology
- Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
- (2016) Francine Foss et al. Journal of Hematology & Oncology
- Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement
- (2016) Kah-Lok Chan et al. LEUKEMIA & LYMPHOMA
- Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells
- (2016) Benigno C. Valdez et al. LEUKEMIA RESEARCH
- HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types?
- (2016) Amer A Beg et al. Epigenomics
- Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma
- (2016) Francine Foss et al. Cancer Medicine
- Romidepsin-associated cardiac toxicity and ECG changes: A case report and review of the literature
- (2016) Zachary T Rivers et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma
- (2016) M. Estela Martinez-Escala et al. JAMA Oncology
- Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data
- (2015) Susan E. Bates et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial
- (2015) Ranjana H. Advani et al. BRITISH JOURNAL OF HAEMATOLOGY
- Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL
- (2015) S. Rozati et al. CLINICAL CANCER RESEARCH
- Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
- (2015) Owen A. O'Connor et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma
- (2015) Ellen J. Kim et al. LEUKEMIA & LYMPHOMA
- Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy
- (2015) Catherine G. Chung et al. Current Hematologic Malignancy Reports
- Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study
- (2015) Jehan Dupuis et al. Lancet Haematology
- Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry
- (2014) F. Ellin et al. BLOOD
- Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
- (2014) Michinori Ogura et al. JOURNAL OF CLINICAL ONCOLOGY
- Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing
- (2014) Datsen George Wei et al. PLoS Pathogens
- Reversible ageusia associated with romidepsin therapy
- (2013) M. R. Cooper et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor
- (2013) A. R. Chakraborty et al. BLOOD
- Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers
- (2013) L. Amiri-Kordestani et al. CLINICAL CANCER RESEARCH
- Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel
- (2013) A. M. Noonan et al. CLINICAL CANCER RESEARCH
- Romidepsin: A Histone Deacetylase Inhibitor for Refractory Cutaneous T-Cell Lymphoma
- (2012) Miryoung Kim et al. ANNALS OF PHARMACOTHERAPY
- Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions
- (2012) O.E. Akilov et al. BRITISH JOURNAL OF DERMATOLOGY
- Romidepsin for Cutaneous T-cell Lymphoma
- (2012) H. M. Prince et al. CLINICAL CANCER RESEARCH
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
- (2012) Barbara Pro et al. JOURNAL OF CLINICAL ONCOLOGY
- Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01
- (2012) Francesco d'Amore et al. JOURNAL OF CLINICAL ONCOLOGY
- Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
- (2012) Bertrand Coiffier et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin
- (2012) Youn H. Kim et al. LEUKEMIA & LYMPHOMA
- Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
- (2011) R. L. Piekarz et al. BLOOD
- Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study
- (2011) Owen A. O'Connor et al. JOURNAL OF CLINICAL ONCOLOGY
- The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells
- (2010) CE Tiffon et al. BRITISH JOURNAL OF PHARMACOLOGY
- Transcriptional Profiles Predict Disease Outcome in Patients with Cutaneous T-Cell Lymphoma
- (2010) I. V. Litvinov et al. CLINICAL CANCER RESEARCH
- Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
- (2010) Cliona Grant et al. Expert Review of Anticancer Therapy
- Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
- (2010) Sean J. Whittaker et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
- (2010) Ewa Lech-Maranda et al. Recent Patents on Anti-Cancer Drug Discovery
- Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
- (2009) L. R. Molife et al. ANNALS OF ONCOLOGY
- Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma
- (2009) Susan E. Bates et al. BRITISH JOURNAL OF HAEMATOLOGY
- Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
- (2009) S. Woo et al. CLINICAL CANCER RESEARCH
- Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
- (2009) Richard L. Piekarz et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started